Kenvue's profitability, with gross margins above 58% and EBITDA margins over 23%, provides resilience against legal and headline risks. Learn more about KVUE stock here.

If you are trying to figure out whether to hold onto your Kenvue shares, add more to your portfolio, or sit this one out, you are definitely not alone. Investors have watched Kenvue’s stock price take a hit lately,

Shares of Kenvue Inc. slid 4.09% to $16.17 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.50% to 6,604.72 and Dow Jones Industrial Average falling 0.

Kenvue shares rose 6% in premarket trading on Tuesday, set to rebound from a record low hit in the previous session as U.S. President Donald Trump linked its popular pain medication Tylenol to autism.

The White House is reportedly planning to link Tylenol use during pregnancy to autism. The news pushed Kenvue stock down 8%.

Families are asking a U.S. appeals court to revive lawsuits against Kenvue and retailers that sold acetaminophen, alleging Tylenol and generic versions of the drug caused autism and ADHD in children,

Kenvue shares declined on Tylenol autism reports, creating a long-term buying opportunity for savvy investors. Click here to read my analysis on KVUE stock.

Alibaba jumps after unveiling plans to boost investments in artificial intelligence, while Lithium Americas soars after a report says the Trump administration is seeking an equity stake in the company.